10x Genomics, Inc. (TXG) Stock
8 of the hedge funds AlphaScala tracks reported TXG in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $383.52M. Company insiders reported 0 open-market buys and 28 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which hedge funds own TXG?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 10.00M | $383.52M | -15% |
| Citadel Ken Griffin | 2.78M | $106.56M | +274% |
| Point72 Steve Cohen | 1.85M | $71.04M | NEW |
| Renaissance Technologies Jim Simons (founder) | 802K | $30.75M | -20% |
| Duquesne Family Office Stanley Druckenmiller | 403K | $15.46M | NEW |
| D.E. Shaw David Shaw | 233K | $8.94M | +240% |
| Millennium Management Israel Englander | 117K | $4.48M | -94% |
| Bridgewater Associates Ray Dalio | 13K | $512.8K | -62% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are 10x Genomics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 22, 26 | Saxonov Serge | Chief Executive Officer | SELL | 1.0K | $78K |
| Sep 22, 26 | Saxonov Serge | Chief Executive Officer | SELL | 2.0K | $159K |
| Sep 22, 26 | Saxonov Serge | Chief Executive Officer | SELL | 9.3K | $752K |
| Sep 22, 26 | Saxonov Serge | Chief Executive Officer | SELL | 9.9K | $810K |
| Sep 22, 26 | Saxonov Serge | Chief Executive Officer | SELL | 2.8K | $231K |
| Sep 22, 26 | Suliman Shehnaaz | Director | SELL | 292 | $23K |
| Sep 22, 26 | Suliman Shehnaaz | Director | SELL | 614 | $49K |
| Sep 22, 26 | Suliman Shehnaaz | Director | SELL | 1.3K | $107K |
| Sep 22, 26 | Suliman Shehnaaz | Director | SELL | 2.3K | $185K |
| Sep 22, 26 | Suliman Shehnaaz | Director | SELL | 1.2K | $101K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →TXG price chart
Powered by TradingViewWhat does 10x Genomics, Inc. do?
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems globally. The company specializes in single cell and spatial biology, enabling researchers to study individual cells and understand complex biological processes at unprecedented resolution. Its primary platforms include Chromium for single cell analysis, which provides transcriptomics, genomics, and epigenomics capabilities, and Visium for spatial gene expression analysis. Additionally, the company offers Xenium, an advanced spatial platform enabling simultaneous RNA and protein detection within tissue samples. 10x Genomics serves academic researchers, biopharmaceutical companies, and translational research institutions across the Americas, Europe, Middle East, Africa, China, and Asia Pacific. The company supports its platforms with integrated software solutions and supplies the microfluidic chips and assays necessary for high-throughput analysis. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics plays a critical role in advancing precision medicine, drug discovery, and disease understanding through its innovative single cell and spatial biology technologies.